NEW YORK, Feb. 21, 2023 /PRNewswire/ -- Caligan Partners LP ("Caligan"), one of the largest shareholders of Anika Therapeutics, Inc. (NASDAQ: ANIK) ("Anika" or the "Company"), today issued an open letter to the board of directors of Anika in connection with Anika's poor share performance, caused by the heavy losses it is incurring in its joint preservation segment, and its failure to maximize the value of Anika's viscosupplement portfolio.
The full text of the letter is in the attached PDF.
About Caligan Partners LP
Caligan Partners LP ("Caligan") is an SEC-registered investment advisor focused on active engagement with small and midcap companies within life sciences.
| Last Trade: | US$9.76 |
| Daily Change: | -0.12 -1.21 |
| Daily Volume: | 71,731 |
| Market Cap: | US$140.740M |
November 05, 2025 November 05, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
